{"id":"NCT01597245","sponsor":"Eli Lilly and Company","briefTitle":"A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05-18","primaryCompletion":"2014-03-25","completion":"2019-06-18","firstPosted":"2012-05-14","resultsPosted":"2016-10-20","lastUpdate":"2020-06-26"},"enrollment":1224,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"80 mg ixekizumab Dosing Regimen","otherNames":["LY2439821"]},{"type":"DRUG","name":"50 mg etanercept","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"80 mg ixekizumab Dosing Regimen 1","type":"EXPERIMENTAL"},{"label":"80 mg ixekizumab Dosing Regimen 2","type":"EXPERIMENTAL"},{"label":"80 mg ixekizumab Dosing Regimen 3","type":"EXPERIMENTAL"},{"label":"50 mg etanercept","type":"ACTIVE_COMPARATOR"},{"label":"Placebo for ixekizumab","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo - Induction Period","deltaMin":2.4,"sd":null},{"arm":"50 mg Etanercept (ETN) - Induction Period","deltaMin":36,"sd":null},{"arm":"Ixe Q4W - Induction Period","deltaMin":72.9,"sd":null},{"arm":"Ixe Q2W - Induction Period","deltaMin":83.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":118,"countries":["United States","Australia","Austria","Canada","Czechia","France","Germany","Netherlands","Poland","Romania","Spain","United Kingdom"]},"refs":{"pmids":["38647975","38521874","37400681","35279805","32845588","32200512","30465321","28074446","27299809","26953848","26072109"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":167},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Injection site reaction","Arthralgia","Headache"]}}